Novo Nordisk (CPSE:NOVO B) received US FDA approval for Awiqli as a once weekly basal insulin for children with type 2 diabetes. Awiqli is indicated as an adjunct to diet and exercise for patients aged 10 years and older requiring long acting insulin treatment. The product introduces a weekly dosing option that may reduce injection frequency for pediatric type 2 diabetes compared with daily basal insulin regimens. The Awiqli approval for children with type 2 diabetes sits alongside deeper trends in Novo Nordisk's diabetes pipeline uncovered by our work. Our analysis turns up 2 warning signs (1 major) for Novo Nordisk as well.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.